This study is currently not recruiting participants.

Roche WB28183: A Phase III Randomized Double-Blind Placebo-Controlled Study to Assess The Efficacy Safety and Tolerability of Lebrikizumab in Adolescent Patients with Uncontrolled Asthma who are on inhaled corticosteroids and a second controller Medication

Study of Investigational Medication for Uncontrolled Asthma

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The proposed clinical development program for lebrikizumab will evaluate whether specific modulation of a type 2 helper T cell (Th2) immune pathway that is mediated by interleukin-13 (IL-13) will improve clinical outcomes in patients with asthma whose disease remains uncontrolled by standard guideline-based therapies.

Detailed description of study

The proposed clinical development program for lebrikizumab will evaluate whether specific modulation of a type 2 helper T cell (Th2) immune pathway that is mediated by interleukin-13 (IL-13) will improve clinical outcomes in patients with asthma whose disease remains uncontrolled by standard guideline-based therapies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: asthma
  • Age: 100 years or below
  • Gender: All

This study investigates how an investigational medication affects people with asthma that is not controlled by usual treatments. Asthma is a condition where the airways in the lungs become narrow and swollen, making it hard to breathe. This study looks at a specific part of the immune system called the type 2 helper T cell (Th2) pathway, which involves a protein called interleukin-13 (IL-13).

Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will measure how well the investigational medication works compared to the placebo in improving asthma symptoms.

  • Who can participate: Adults aged 18 and over with asthma that is not controlled by standard treatments are eligible to participate.
  • Study details: Participants will receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1404893044

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team